Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic ...
DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be ...
ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 ...
MeiraGTx will present four posters at the ASGCT 2025 Annual Meeting regarding genetic therapies for obesity and ALS. Quiver AI Summary MeiraGTx Holdings plc announced its participation in the American ...
SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ...
CinFina Pharma to Present Posters Demonstrating the Potential of New Mechanisms at ObesityWeek® 2024
CINCINNATI--(BUSINESS WIRE)--CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity, will present two posters at ObesityWeek® 2024, ...
CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- MetaVia Inc. (MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that two abstracts ...
Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous ...
ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results